Therapeutic | Isatuximab |
Target | CD38 |
Heavy Chain | QVQLVQSGAEVAKPGTSVKLSCKASGYTFTDYWMQWVKQRPGQGLEWIGTIYPGDGDTGYAQKFQGKATLTADKSSKTVYMHLSSLASEDSAVYYCARGDYYGSNSLDYWGQGTSVTVSS |
Light Chain | DIVMTQSHLSMSTSLGDPVSITCKASQDVSTVVAWYQQKPGQSPRRLIYSASYRYIGVPDRFTGSGAGTDFTFTISSVQAEDLAVYYCQQHYSPPYTFGGGTKLEIK |
100% seqID Fv Structure | 4cmh%3ABC [Fvs: ] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 4cmh%3ABC [Fvs: ] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (August '23) | Preregistration |
Estimated Status (August '23) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2014 |
INN Year Recommended | 2015 |
Companies Involved | ImmunoGen%3BHuntsman Cancer Institute%3BRoche%3BSanofi |
Conditions Approved | na |
Conditions Active | Multiple myeloma%3BAcute myeloid leukaemia%3BPrecursor cell lymphoblastic leukaemia-lymphoma%3BT-cell lymphoma%3BColorectal cancer%3BDiffuse large B cell lymphoma%3BHodgkin%27s disease%3BNon-small cell lung cancer%3BPeripheral T-cell lymphoma%3BProstate cancer%3BSolid tumours%3BUrogenital cancer |
Conditions Discontinued | na |
Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]